Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natural Products: Back In Vogue?

This article was originally published in Start Up

Executive Summary

Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.
Advertisement

Related Content

Lilly To Cease Development Of Alzheimer's Drug
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads
Reimbursement: The New Biopharma Investment Hurdle
As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Dealmaking When Pharma's the Only Game in Town
Dealmaking When Pharma's the Only Game in Town

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel